Drug Development

Positive phase IIa data reported for Rambazole and Azoline in fungal infections

Published in Drug Week, February 11th, 2005

Barrier Therapeutics, Inc., (BTRX), a pharmaceutical company developing products in the field of dermatology, reported positive phase IIa data for both oral Rambazole in the treatment of psoriasis, and for oral Azoline in the treatment of superficial fungal infections.

Rambazole is a novel retinoic acid metabolism-blocking agent (RAMBA). A review of initial phase IIa trial data from 10 patients with moderate to severe psoriasis demonstrated a reduction in the PASI score (a symptom severity score in psoriatic patients) by an average of 50% in patients treated with 1mg once daily for 8 consecutive weeks.

These PASI scores were measured at week 10, 2...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-02-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry